StockNews.AI
IBRX
StockNews.AI
25 days

ImmunityBio Reports 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 Million and 246% Unit Growth Since J-Code with Regulatory Updates

1. IBRX reported $26.4 million revenue, up 60% from Q1 2025. 2. ANKTIVA® unit sales grew 246% in 1H 2025 over 2H 2024.

2m saved
Insight
Article

FAQ

Why Bullish?

The significant revenue growth and unit sales increase suggest strong market traction, mirroring past successful quarters that led to positive stock performance for IBRX.

How important is it?

The reported revenue growth and sales momentum suggest a robust pipeline and market interest, which are crucial for stock performance.

Why Short Term?

Immediate financial results indicate potential for quick investor sentiment change, as seen when previous earnings exceeded expectations.

Related Companies

ANKNVAXCURE
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced preliminary financial results for the fiscal quarter ended June 30, 2025, and clinical progress across its pipeline. Key Highlights Q2 2025 Revenue Growth with Continued Strong Sales Momentum: $26.4 million, up 60% from Q1 2025, with year-to-date sales of ~$43 million. ANKTIVA® Unit Growth Since J-Code: 246% unit sales volume growth in 1H 2025 compared to 2H 2024. Cash Positi.

Related News